I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Edward Kaye Biography and Net Worth

Director of Cytokinetics

Dr. Kaye has served as a member of our Board of Directors since May 2016. He is the Chief Executive Officer of Stoke Therapeutics. Previously, he served as the Chief Executive Officer of Sarepta, as well as the Chief Medical Officer, from 2011 to 2017. Prior to joining Sarepta, Dr. Kaye was employed by Genzyme Corporation for ten years, holding various senior management positions, the most recent of which was Group Vice President of Clinical Development, in which he supervised clinical research in lysosomal storage disease programs and genetic neurological disorders. Previously, Dr. Kaye served as Chief of Biochemical Genetics at Children’s Hospital of Philadelphia and Associate Professor of Neurology and Pediatrics at the University Of Pennsylvania School Of Medicine. Dr. Kaye serves as a Neurological Consultant at the Children’s Hospital of Boston and is on the editorial boards of a number of medical journals. He is also a member of several scientific advisory boards, including United Leukodystrophy Foundation, Spinal Muscular Atrophy Foundation, CureCMD, CureDuchenne and Prize4Life. Dr. Kaye received his medical education and pediatric training at Loyola University Stritch School of Medicine and University Hospital, child neurology training at Boston City Hospital, Boston University, and completed his training as a neurochemical research fellow at Bedford VA Hospital, Boston University.

What is Edward M. Kaye's net worth?: The estimated net worth of Edward M. Kaye is at least $2.94 million as of December 9th, 2024. Dr. Kaye owns 61,885 shares of Cytokinetics stock worth more than $2,939,538 as of December 30th. This net worth evaluation does not reflect any other investments that Dr. Kaye may own. Learn More about Edward M. Kaye's net worth.
How do I contact Edward M. Kaye?: The corporate mailing address for Dr. Kaye and other Cytokinetics executives is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. Cytokinetics can also be reached via phone at (650) 624-3000 and via email at [email protected]. Learn More on Edward M. Kaye's contact information.
Has Edward M. Kaye been buying or selling shares of Cytokinetics?: Edward M. Kaye has not been actively trading shares of Cytokinetics within the last three months. Most recently, Edward M. Md Kaye sold 15,000 shares of the business's stock in a transaction on Thursday, December 23rd. The shares were sold at an average price of $45.00, for a transaction totalling $675,000.00. Learn More on Edward M. Kaye's trading history.
Who are Cytokinetics' active insiders?: Cytokinetics' insider roster includes Muna Bhanji (Director), Robert Blum (President and Chief Executive Officer), Santo Costa (Director), David Cragg (Insider), L. Gage (Director), Robert Harrington (Director), John Henderson (Director), Ching Jaw (CFO), Edward Kaye (Director), Fady Malik (EVP), B. Parshall (Director), Mark Schlossberg (SVP), Sandford Smith (Director), Wendall Wierenga (Director), and Robert Wong (CAO). Learn More on Cytokinetics' active insiders.
Are insiders buying or selling shares of Cytokinetics?: During the last year, insiders at the biopharmaceutical company sold shares 47 times. They sold a total of 444,133 shares worth more than $27,870,030.33. The most recent insider tranaction occured on December, 16th when Director Wendall Wierenga sold 742 shares worth more than $36,068.62. Insiders at Cytokinetics own 3.4% of the company. Learn More about insider trades at Cytokinetics.
Information on this page was last updated on 12/16/2024.

Edward M. Kaye Insider Trading History at Cytokinetics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/23/2021	Sell	15,000	$45.00	$675,000.00

Edward M. Kaye Buying and Selling Activity at Cytokinetics

Cytokinetics Company Overview

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Today's Range

Now: $47.50

$46.52

$47.79

50 Day Range

MA: $51.32

$46.36

$58.62

2 Week Range

Now: $47.50

$45.66

$110.25

Volume

315,793 shs

Average Volume

1,963,885 shs

Market Capitalization

$5.61 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.8

I was wrong. Dead wrong.

From Porter & Company | Ad